Antabio
Infectious Disease Therapeutics · Health Care
$31.4MTotal raised
10–19EmployeesFrench register · Dec 2023 ↗
Data updated Nov 20, 2026Money ledger: 3 records from 3 sourcesFiled 1Announced 2Full reportReport a mistake
Facts
as of Nov 20, 2026Antabio develops novel antibiotics against drug-resistant Gram-negative bacteria and antimicrobial resistance.
- Legal name
- ANTABIO Limitedactive
- Headquarters
- Labège, France
- Founded
- 2009
- Employees
- 10–19French register · Dec 2023
- Register numbers
- SIREN 517511291 · VAT FR94517511291
- Official records
- Wikidata Q112112502
- Website
- antabio.com
These are the key facts about Antabio on Alion as of Nov 20, 2026. Antabio is headquartered in Labège, France. It was founded in 2009. It has raised $31.4M in 2 funding rounds. The latest round is Series B of $27M, announced in 2023.
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake
Funding
Full ledger, 3 records →Antabio has $31.4M paid in by investors, lenders and donors.
$31.4MPaid in
Money innewest first
$27MPaid
$2.7MPaid
$4.4MPaid
Money by yearUSD, rounds and grants
Every row links its own source. A flow two sources state counts once; a figure a source does not state reads "not stated".
People
10–19EmployeesFrench register · Dec 2023
Products
Products →Antabio has 3 clinical trials on record, 0 under way.
Clinical trials
Evaluation of the Concentration of ANT3310 and Meropenem in the Lung in Healthy Adult Participants
phase 1 · completed · 26 participants · Pharmacokinetics Study on Healthy Volunteers Adults
Apr 2025
Assessment of the Pharmacokinetics and Safety of ANT3310 Combined With Meropenem in Renally Impaired Subjects
phase 1 · completed · 41 participants · Renal Impairment
Jul 2024
FiH Study to Assess Safety and PK of SAD and MAD of ANT3310 Alone and in Combination With Meropenem in Healthy Subjects
phase 1 · completed · 72 participants · Healthy Volunteers
Apr 2023
Source: each app’s App Store and Google Play page (an app counts as the company’s when its developer site is on the company’s domain); the products its own site names.
Risk
Full record →Antabio: EUR 0–10,000 of EU lobbying in 2025.
Yes
No match
None
EUR 0–10,000
Patents
8
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
Milestones
Sources: the outlets named on each headline, each story once
Footprint
Hiring in 1 city in 1 country.
1Cities
1Countries
| Site | Type | Open roles | Hires most for | Engineering |
|---|---|---|---|---|
| Labège France | Headquarters | 0 |
Source: office addresses in postings and company registers
